查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1874000

癌症疫苗市場

Cancer Vaccines Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024年，癌症疫苗市場規模約為78.7億美元，預計將成長至168.6億美元，預測期內年複合成長率（CAGR）為11.5%。癌症疫苗市場的主要趨勢預計包括：開發個人化癌症疫苗、重視聯合療法以及增加對癌症疫苗研發的投資。

癌症疫苗市場分析

全球癌症發生率的上升可能會推動癌症疫苗市場的成長。癌症仍然是全球主要死因之一，並嚴重影響患者的生活品質。如果未能及時診斷和治療，癌症將給社會帶來沉重的負擔。世界衛生組織的報告顯示，2022年全球報告的癌症病例約為19,976,499例，預計到2045年，這一數字將上升至3,260萬例。

癌症在各個地區的日益流行，推動了全球對疫苗的需求。

癌症疫苗市場概覽

全球癌症疫苗市場按地區分類為北美、歐洲、亞太、中東和非洲以及南美和中美洲。預計這些地區的成長將得益於全球癌症發病率的上升以及衛生研究機構和主要行業參與者專注於癌症疫苗研發的舉措。然而，商業上可行的癌症治療疫苗供應有限且價格高昂，可能會在預測期內在一定程度上阻礙市場成長。

戰略洞察

癌症疫苗市場的促進因素與機遇

支持癌症疫苗的全球衛生計劃

新興市場：癌症疫苗領域的機遇

亞太地區的發展中國家為主要市場參與者提供了龐大的業務拓展機會。許多公司將目光投向印度和中國等新興市場，因為這些地區癌症患者數量眾多，醫療旅遊業蓬勃發展。根據馬來西亞醫療旅遊理事會統計，2022年有超過85萬名醫療遊客前往馬來西亞就醫。手術費用較低，先進技術普及，等待時間短，這些因素吸引全球患者前往這些發展中國家接受包括癌症篩檢在內的醫療服務。癌症發生率的上升進一步拓展了市場機會；例如，印度在2022年新增癌症病例約1413316例。因此，醫療旅遊業的蓬勃發展和新興市場的癌症發病率上升，為產業參與者提供了巨大的成長前景。

對癌症疫苗市場進行分析的關鍵細分市場包括服務和應用。

  • 依技術分類，癌症疫苗市場可分為樹突細胞癌症疫苗、重組癌症疫苗、抗原癌症疫苗、全細胞癌症疫苗和病毒載體癌症疫苗。 2023年，重組癌症疫苗佔據最大的市場佔有率，預計在預測期內將維持最高的複合年成長率。
  • 按類型分類，癌症疫苗市場分為預防性癌症疫苗和治療性癌症疫苗。 2023年，預防性癌症疫苗市場佔據主導地位，預計在預測期內將維持最高的複合年成長率。
  • 依適應症分類，市場可分為子宮頸癌、攝護腺癌和其他適應症。 2023年，子宮頸癌細分市場佔據最大的市場佔有率，預計在預測期內將保持最高的複合年成長率。
  • 市場依最終用戶分為兒科和成人兩大類。 2023年，兒科市場佔據最大的市場佔有率，預計在預測期內將呈現最高的複合年成長率。

癌症疫苗市場的地理分析

癌症疫苗市場報告的地理範圍分為五個區域：北美、亞太、歐洲、中東和非洲以及南美/南美和中美洲。

2023年，包括美國、加拿大和墨西哥在內的北美地區在全球市場佔據了相當大的佔有率。由於癌症診斷和治療需求的增加、癌症發病率的上升、大量的研發投資、市場參與者之間日益激烈的競爭以及政府對研究機構開發新療法的資助等因素，預計該地區的需求在預測期內將以顯著的速度成長。

亞太地區是全球癌症疫苗市場成長最快的地區，這主要得益於日本和中國等國家在癌症疫苗研發上的進步。該地區龐大的癌症患者群體、不斷增加的研究項目、日益成長的政府支持以及新創企業和生物技術公司的湧現，都為市場成長提供了機會。

癌症疫苗市場報告範圍

癌症疫苗市場最新動態

癌症疫苗市場評估是基於從一手和二手研究中收集的定性和定量資料，包括重要的企業出版物、協會資料和資料庫。以下是癌症疫苗市場的一些最新發展和策略：

  • 2023年12月，牛津大學醫院啟動了一項針對頭頸癌患者的新型mRNA癌症疫苗試驗。 （來源：公司新聞稿）
  • 2024年2月，Moderna公司在帝國學院醫療保健NHS信託基金啟動了其癌症疫苗mRNA-4359的臨床試驗，旨在評估該療法對黑色素瘤、肺癌和其他實體瘤的安全性和潛在療效。 （來源：公司新聞稿）

癌症疫苗市場報告的覆蓋範圍和交付成果

這份題為《癌症疫苗市場規模及預測（2021-2031）》的報告對市場進行了全面分析，涵蓋以下領域：

  • 涵蓋範圍內所有關鍵細分市場的全球、區域和國家層面的市場規模和預測
  • 市場動態，包括促進因素、限制因素和關鍵機會
  • 未來主要趨勢
  • 詳細的PEST/波特五力模型與SWOT分析
  • 全球及區域市場分析，重點在於關鍵趨勢、主要參與者、法規及最新發展。
  • 產業格局和競爭分析，包括市場集中度、熱力圖分析、主要參與者和最新發展動態
  • 深入的公司概況

目錄

第1章：引言

第2章：癌症疫苗市場及主要結論

第3章：研究方法

  • 覆蓋範圍
  • 二手研究
  • 初步研究

第4章：全球癌症疫苗市場及市場概況

  • 概述
  • PEST分析
    • 北美和PEST分析
    • 歐洲和PEST分析
    • 亞太地區及PEST分析
    • 中東和非洲 (MEA) 及 PEST 分析
    • 南美洲和中美洲（SCAM）及PEST分析
  • 專家意見

第5章：癌症疫苗市場及主要市場動態

  • 主要市場促進因素
    • 全球癌症發生率上升
    • 全球衛生研究組織和關鍵參與者在癌症疫苗領域的舉措
  • 主要市場限制因素
    • 市售癌症治療疫苗數量減少
    • 癌症疫苗成本更高
  • 主要市場機遇
    • 發展中國家的新興市場
  • 未來趨勢
    • 不斷成長的研發活動
  • 影響分析

第6章：癌症疫苗市場及全球分析

  • 全球癌症疫苗市場收入預測與分析
  • 全球癌症疫苗市場（依地域分類）－預測與分析
  • 關鍵參與者的市場定位

第7章：癌症疫苗市場及技術分析

  • 概述
  • 癌症疫苗市場（按技術分類），2024 年和 2031 年（%）
  • 樹突細胞癌症疫苗
  • 重組癌症疫苗
  • 抗原癌症疫苗
  • 全細胞癌症疫苗
  • 病毒載體癌症疫苗

第8章：癌症疫苗市場分析及類型分類

  • 概述
  • 癌症疫苗市場收入佔有率（按類型分類）（2024 年和 2031 年）
  • 預防性癌症疫苗
  • 治療性癌症疫苗

第9章：癌症疫苗市場分析及適應症

  • 概述
  • 癌症疫苗市場收入佔有率（按適應症分類）（2024 年和 2031 年）
  • 子宮頸癌
  • 攝護腺癌
  • 其他適應症

第10章：癌症疫苗市場分析及最終用途

  • 概述
  • 癌症疫苗市場收入佔有率（按最終用途分類）（2024 年和 2031 年）
  • 兒科
  • 成年人

第11章：癌症疫苗市場分析及至2031年預測－地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
  • 南美洲和中美洲
    • 巴西
    • 阿根廷

第12章：新冠肺炎疫情對全球癌症疫苗市場的影響

  • 北美洲
  • 歐洲
  • 亞太
  • 世界其他地區

第13章：癌症疫苗市場及產業概況

  • 概述
  • 市場中各公司採取的成長策略（%）
  • 有機發展
    • 概述
  • 無機物發展
    • 概述

第14章：公司簡介

  • CSL Limited
  • ADURO BIOTECH INC.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
  • Dendreon
  • AstraZeneca
  • Merck and Co., Inc.
  • Sanofi (Sanofi Pasteur)
  • OSE Immunotherapeutics

第15章：附錄

簡介目錄
Product Code: TIPRE00004595

The cancer vaccines market was valued at approximately US$ 7.87 billion in 2024 and is anticipated to grow to US$ 16.86 billion, with a compound annual growth rate (CAGR) of 11.5% throughout the forecast period. Key trends in the cancer vaccines market are expected to include the development of personalized cancer vaccines, an emphasis on combination therapies, and increased investments in research and development for cancer vaccines.

Analysis of the Cancer Vaccines Market

The rising global incidence of cancer is likely to propel the growth of the cancer vaccines market. Cancer remains one of the leading causes of death worldwide and significantly impacts quality of life. If not diagnosed and treated promptly, cancer poses a substantial burden on society. According to a report from the World Health Organization, there were approximately 19,976,499 cancer cases reported in 2022, with projections estimating that this number will rise to 32.6 million by 2045.

This increasing prevalence of cancer across various regions is driving the global demand for vaccines.

Overview of the Cancer Vaccines Market

The global cancer vaccines market is categorized by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. Growth in these regions is anticipated due to factors such as the rising prevalence of cancer globally and initiatives by health research organizations and key industry players focused on cancer vaccines. However, the limited availability of commercially viable cancer treatment vaccines and their high costs may hinder market growth to some extent during the forecast period.

Strategic Insights

Drivers and Opportunities in the Cancer Vaccines Market

Global Health Initiatives Supporting Cancer Vaccines

Emerging Markets: Opportunities in the Cancer Vaccines Sector

Developing nations in the Asia-Pacific region are presenting substantial business expansion opportunities for major market players. Many companies are focusing on emerging markets like India and China due to the high number of cancer patients and the growth of medical tourism in these areas. According to the Malaysia Healthcare Travel Council, over 850,000 healthcare travelers visited Malaysia in 2022 for various medical needs. The lower costs of surgeries and the availability of advanced technologies with minimal waiting times are attracting global patients to these developing countries for medical procedures, including cancer screenings. The rising incidence of cancer is creating further opportunities in the market; for example, India recorded approximately 1,413,316 new cancer cases in 2022. Thus, the surge in medical tourism and the increasing prevalence of cancer in emerging markets are providing significant growth prospects for industry players.

Key segments contributing to the analysis of the cancer vaccines market include services and applications.

  • The market is segmented by technology into dendritic cell cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, and viral vector cancer vaccines. The recombinant cancer vaccines segment held the largest market share in 2023 and is expected to exhibit the highest CAGR during the forecast period.
  • By type, the market is divided into preventive cancer vaccines and therapeutic cancer vaccines. The preventive cancer vaccines segment dominated the market in 2023 and is projected to have the highest CAGR in the forecast period.
  • By indication, the market is categorized into cervical cancer, prostate cancer, and other indications. The cervical cancer segment accounted for the largest market share in 2023 and is expected to register the highest CAGR during the forecast period.
  • The market is segmented by end-user into pediatrics and adults. The pediatrics segment held the largest market share in 2023 and is anticipated to show the highest CAGR in the forecast period.

Geographical Analysis of the Cancer Vaccines Market

The geographical scope of the cancer vaccines market report is divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South America/South & Central America.

North America, which includes the US, Canada, and Mexico, held a significant share of the global market in 2023. The demand in this region is expected to grow at a notable rate during the forecast period due to factors such as the increasing need for cancer diagnosis and treatment, rising cancer incidence, substantial R&D investments, heightened competition among market players, and government funding for research institutions to develop new therapies.

The Asia Pacific region is the fastest-growing market for cancer vaccines globally, driven by advancements in cancer vaccine development in countries like Japan and China. The large population of cancer patients, an increasing number of research initiatives, growing government support, and a rise in startups and biotech firms in this region are contributing to market growth opportunities.

Scope of the Cancer Vaccines Market Report

Recent Developments in the Cancer Vaccines Market

The cancer vaccines market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the cancer vaccines market:

  • In December 2023, Oxford University Hospitals initiated a new mRNA cancer vaccine trial for patients with head and neck cancers. (Source: Company Press Release)
  • In February 2024, Moderna began trials for its cancer vaccine mRNA-4359 at Imperial College Healthcare NHS Trust, aiming to evaluate the safety and potential efficacy of the treatment for melanoma, lung cancer, and other solid tumors. (Source: Company Press Release)

Coverage and Deliverables of the Cancer Vaccines Market Report

The report titled "Cancer Vaccines Market Size and Forecast (2021-2031)" provides a comprehensive analysis of the market, covering the following areas:

  • Market size and forecasts at global, regional, and country levels for all key segments included in the scope
  • Market dynamics, including drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis highlighting key trends, major players, regulations, and recent developments
  • Industry landscape and competition analysis, including market concentration, heat map analysis, prominent players, and recent developments
  • In-depth company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Cancer Vaccines Market and By Technology
    • 1.3.2 Global Cancer Vaccines Market and By Type
    • 1.3.3 Global Cancer Vaccines Market and By Indication
    • 1.3.4 Global Cancer Vaccines Market and By End-User
    • 1.3.5 Global Cancer Vaccines market and By Geography

2. Cancer Vaccines Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Global Cancer Vaccines Market and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 North America and PEST Analysis
    • 4.2.2 Europe and PEST Analysis
    • 4.2.3 Asia Pacific and PEST Analysis
    • 4.2.4 Middle East and Africa (MEA) and PEST Analysis
    • 4.2.5 South and Central America (SCAM) and PEST Analysis
  • 4.3 Expert Opinions

5. Cancer Vaccines Marketand Key Market Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Increase in Prevalence of Cancer Worldwide
    • 5.1.2 Initiatives Taken by Global Health Research Organizations and Key Players for Cancer Vaccines
  • 5.2 Key Market Restraints
    • 5.2.1 Less Number of Commercially Available Vaccines for Treatment of Cancer
    • 5.2.2 Higher Cost of Cancer Vaccines
  • 5.3 Key Market Opportunities
    • 5.3.1 Emerging Markets in Developing Countries
  • 5.4 Future Trends
    • 5.4.1 Growing Research and Development Activities
  • 5.5 Impact analysis

6. Cancer Vaccines Market and Global Analysis

  • 6.1 Global Cancer Vaccines Market Revenue Forecast and Analysis
  • 6.2 Global Cancer Vaccines Market, By Geography - Forecast And Analysis
  • 6.3 Market Positioning of Key Players

7. Cancer Vaccines Market and By Technology

  • 7.1 Overview
  • 7.2 Cancer Vaccines Market, by Technology, 2024 and 2031 (%)
  • 7.3 Dendritic Cells Cancer Vaccine
    • 7.3.1 Overview
    • 7.3.2 Dendritic Cells Cancer Vaccines : Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Recombinant Cancer Vaccines
    • 7.5.1 Overview
    • 7.5.2 Recombinant Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Antigen Cancer Vaccines
    • 7.6.1 Overview
    • 7.6.2 Antigen Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.7 Whole Cell Cancer Vaccines
    • 7.7.1 Overview
    • 7.7.2 Whole Cell Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  • 7.8 Viral Vector Cancer Vaccines
    • 7.8.1 Overview
    • 7.8.2 Viral Vector Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)

8. Cancer Vaccines Market Analysis and By Type

  • 8.1 Overview
  • 8.2 Cancer Vaccines Market Revenue Share, by Type (2024 and 2031)
  • 8.3 Preventive Cancer Vaccines
    • 8.3.1 Overview
    • 8.3.2 Preventive Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Therapeutic Cancer Vaccines
    • 8.4.1 Overview
    • 8.4.2 Therapeutic Cancer Vaccines: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)

9. Cancer Vaccines Market Analysis and By Indication

  • 9.1 Overview
  • 9.2 Cancer Vaccines Market Revenue Share, by Indication (2024 and 2031)
  • 9.3 Cervical Cancer
    • 9.3.1 Overview
    • 9.3.2 Cervical Cancer: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Prostate Cancer
    • 9.4.1 Overview
    • 9.4.2 Prostate Cancer: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  • 9.5 Other Indications
    • 9.5.1 Overview
    • 9.5.2 Other Indications: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)

10. Cancer Vaccines Market Analysis and By End Use

  • 10.1 Overview
  • 10.2 Cancer Vaccines Market Revenue Share, by End Use (2024 and 2031)
  • 10.3 Pediatrics
    • 10.3.1 Overview
    • 10.3.2 Pediatrics: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Adults
    • 10.4.1 Overview
    • 10.4.2 Adults: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)

11. Cancer Vaccines Market Analysis And Forecasts To 2031 Geographical Analysis

  • 11.1 North America: Cancer Vaccines Market
    • 11.1.1 Overview
    • 11.1.2 North America: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
    • 11.1.3 North America: Cancer Vaccines Market, by Technology, 2024 and 2031 (USD Million)
    • 11.1.4 North America: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
    • 11.1.5 North America: Cancer Vaccines Market, by Indication, 2024 and 2031 (USD Million)
    • 11.1.6 North America: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.1.7 North America: Cancer Vaccines Market, by Country, 2024 and 2031 (%)
    • 11.1.8 US: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.1.8.1 US: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.1.8.2 US: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.1.8.3 US: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.1.8.4 US: Cancer Vaccines Market, by Technology2024 and 2031 (USD Million)
      • 11.1.8.5 US: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.1.9 Canada: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.1.9.1 Canada: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.1.9.2 Canada: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.1.9.3 Canada: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.1.9.4 Canada: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.1.9.5 Canada: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.1.10 Mexico: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.1.10.1 Mexico: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.1.10.2 Mexico: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.1.10.3 Mexico: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.1.10.4 Mexico: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.1.10.5 Mexico: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
  • 11.2 Europe: Cancer Vaccines Market
    • 11.2.1 Overview
    • 11.2.2 Europe: Cancer Vaccines Market - Revenue and Forecast to 2031 (USD Million)
    • 11.2.3 Europe: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
    • 11.2.4 Europe: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
    • 11.2.5 Europe: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
    • 11.2.6 Europe: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.2.7 Europe: Cancer Vaccines Market, by Country, 2018 and 2031 (%)
    • 11.2.8 Germany: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.8.1 Germany: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.8.2 Germany: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.2.8.3 Germany: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.2.8.4 Germany: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.2.8.5 Germany: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.2.9 UK: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.9.1 UK: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.9.2 UK: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.2.9.3 UK: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.2.9.4 UK: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.2.9.5 UK: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.2.10 France: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.10.1 France: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.10.2 France: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.2.10.3 France: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.2.10.4 France: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.2.10.5 France: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.2.11 Spain: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.11.1 Spain: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.11.2 Spain: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.2.11.3 Spain: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.2.11.4 Spain: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.2.11.5 Spain: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.2.12 Italy: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.12.1 Italy: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.2.12.2 Italy: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.2.12.3 Italy: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.2.12.4 Italy: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.2.12.5 Italy: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
  • 11.3 Asia Pacific: Cancer Vaccines Market
    • 11.3.1 Overview
    • 11.3.2 Asia Pacific: Cancer Vaccines Market - Revenue and Forecast to 2031 (USD Million)
    • 11.3.3 Asia Pacific: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
    • 11.3.4 Asia Pacific: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
    • 11.3.5 Asia Pacific: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
    • 11.3.6 Asia Pacific: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.3.7 Asia Pacific: Cancer Vaccines Market, by Country, 2018 and 2031 (%)
    • 11.3.8 China: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.8.1 China: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.8.2 China: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.3.8.3 China: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.3.8.4 China: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.3.8.5 China: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.3.9 Japan: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.9.1 Japan: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.9.2 Japan: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.3.9.3 Japan: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.3.9.4 Japan: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.3.9.5 Japan: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.3.10 India: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.10.1 India: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.10.2 India: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.3.10.3 India: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.3.10.4 India: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.3.10.5 India: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.3.11 South Korea: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.11.1 South Korea: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.11.2 South Korea: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.3.11.3 South Korea: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.3.11.4 South Korea: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.3.11.5 South Korea: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.3.12 Australia: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.12.1 Australia: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.3.12.2 Australia: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.3.12.3 Australia: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.3.12.4 Australia: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.3.12.5 Australia: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
  • 11.4 Middle East and Africa: Cancer Vaccines Market
    • 11.4.1 Overview
    • 11.4.2 Middle East and Africa: Cancer Vaccines Market - Revenue and Forecast to 2031 (USD Million)
    • 11.4.3 Middle East and Africa: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
    • 11.4.4 Middle East and Africa: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
    • 11.4.5 Middle East and Africa: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
    • 11.4.6 Middle East and Africa: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.4.7 Middle East and Africa: Cancer Vaccines Market Share by Country and 2024 and 2031, (%)
    • 11.4.8 Saudi Arabia: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.4.8.1 Saudi Arabia: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.4.8.2 Saudi Arabia: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.4.8.3 Saudi Arabia: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.4.8.4 Saudi Arabia: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.4.8.5 Saudi Arabia: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.4.9 UAE: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.4.9.1 UAE: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.4.9.2 UAE: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.4.9.3 UAE: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.4.9.4 UAE: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.4.9.5 UAE: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
    • 11.4.10 South Africa: Cancer Vaccines Market and Revenue and Forecast to 2031 (US$ Million)
      • 11.4.10.1 South Africa: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.4.10.2 South Africa: Cancer Vaccines Market, by Type, 2024 and 2031 (USD Million)
      • 11.4.10.3 South Africa: Cancer Vaccines Market, by Indication 2024 and 2031 (USD Million)
      • 11.4.10.4 South Africa: Cancer Vaccines Market, by Technology 2024 and 2031 (USD Million)
      • 11.4.10.5 South Africa: Cancer Vaccines Market, by End User, 2024 and 2031 (USD Million)
  • 11.5 South and Central America: Cancer Vaccines Market
    • 11.5.1 Overview
    • 11.5.2 South and Central America: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
    • 11.5.3 South and Central America Cancer Vaccines Market, by Type and Revenue and Forecast to 2031 (USD Million)
    • 11.5.4 South and Central America Cancer Vaccines Market, by Indication and Revenue and Forecast to 2031 (USD Million)
    • 11.5.5 South and Central America Cancer Vaccines Market, by Technology and Revenue and Forecast to 2031 (USD Million)
    • 11.5.6 South and Central America Cancer Vaccines Market, by End User and Revenue and Forecast to 2031 (USD Million)
    • 11.5.7 South and Central America: Cancer Vaccines Market, by Country, 2024 and 2031 (%)
    • 11.5.8 Brazil: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.5.8.1 Brazil: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.5.8.2 Brazil Cancer Vaccines Market, by Type and Revenue and Forecast to 2031 (USD Million)
      • 11.5.8.3 Brazil Cancer Vaccines Market, by Indication and Revenue and Forecast to 2031 (USD Million)
      • 11.5.8.4 Brazil Cancer Vaccines Market, by Technology and Revenue and Forecast to 2031 (USD Million)
      • 11.5.8.5 Brazil Cancer Vaccines Market, by End User and Revenue and Forecast to 2031 (USD Million)
    • 11.5.9 Argentina: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.5.9.1 Argentina: Cancer Vaccines Market and Revenue and Forecast to 2031 (USD Million)
      • 11.5.9.2 Argentina Cancer Vaccines Market, by Type and Revenue and Forecast to 2031 (USD Million)
      • 11.5.9.3 Argentina Cancer Vaccines Market, by Indication and Revenue and Forecast to 2031 (USD Million)
      • 11.5.9.4 Argentina Cancer Vaccines Market, by Technology and Revenue and Forecast to 2031 (USD Million)
      • 11.5.9.5 Argentina Cancer Vaccines Market, by End User and Revenue and Forecast to 2031 (USD Million)

12. Impact Of COVID-19 Pandemic On Global Cancer Vaccines Market

  • 12.1 North America: Impact Assessment of COVID-19 Pandemic
  • 12.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 12.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
  • 12.4 Rest of World: Impact Assessment of COVID-19 Pandemic

13. Cancer Vaccines Market and Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies Done by the Companies in the Market, (%)
  • 13.3 Organic Developments
    • 13.3.1 Overview
  • 13.4 Inorganic Developments
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 CSL Limited
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 ADURO BIOTECH INC.
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Astellas Pharma Inc.
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Bristol-Myers Squibb Company
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 GlaxoSmithKline plc.
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Dendreon
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 AstraZeneca
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Merck and Co., Inc.
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 Sanofi (Sanofi Pasteur)
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 OSE Immunotherapeutics
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms